Cargando…

One-year rehospitalisation and mortality after acute heart failure hospitalisation: a competing risk analysis

OBJECTIVE: To identify factors that independently predict the risk of rehospitalisation and death after acute heart failure (AHF) hospital discharge in a real-world setting, considering death without rehospitalisation as a competing event. METHODS: Single-centre, retrospective, observational study e...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques, Irene, Mendonça, Denisa, Teixeira, Laetitia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030761/
https://www.ncbi.nlm.nih.gov/pubmed/36941025
http://dx.doi.org/10.1136/openhrt-2022-002167
_version_ 1784910448584294400
author Marques, Irene
Mendonça, Denisa
Teixeira, Laetitia
author_facet Marques, Irene
Mendonça, Denisa
Teixeira, Laetitia
author_sort Marques, Irene
collection PubMed
description OBJECTIVE: To identify factors that independently predict the risk of rehospitalisation and death after acute heart failure (AHF) hospital discharge in a real-world setting, considering death without rehospitalisation as a competing event. METHODS: Single-centre, retrospective, observational study enrolling 394 patients discharged from an index AHF hospitalisation. Overall survival was evaluated using Kaplan-Meier and Cox regression models. For the risk of rehospitalisation, survival analysis considering competing risks was performed: rehospitalisation was the event of interest, and death without rehospitalisation was the competing event. RESULTS: During the first year after discharge, 131 (33.3%) patients were rehospitalised for AHF and 67 (17.0%) died without being readmitted; the remaining 196 patients (49.7%) lived without further hospitalisations. The 1-year overall survival estimate was 0.71 (SE=0.02). After adjusting for gender, age and left ventricle ejection fraction, the results showed that the risk of death was higher in patients with dementia, higher levels of plasma creatinine (PCr), lower levels of platelet distribution width (PDW) and at Q4 of red cell distribution width (RDW). Multivariable models showed that the risk of rehospitalisation was increased in patients with atrial fibrillation, higher PCr or taking beta-blockers at discharge. Furthermore, the risk of death without AHF rehospitalisation was higher in males, those aged ≥80 years, patients with dementia or RDW at Q4 on admission (compared with Q1). Taking beta-blockers at discharge and having a higher PDW on admission reduced the risk of death without rehospitalisation. CONCLUSION: When assessing rehospitalisation as a study endpoint, death without rehospitalisation should be considered a competing event in the analyses. Data from this study reveal that patients with atrial fibrillation, renal dysfunction or taking beta-blockers are more likely to be rehospitalised for AHF, while older men with dementia or high RDW are more prone to die without hospital readmission.
format Online
Article
Text
id pubmed-10030761
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-100307612023-03-23 One-year rehospitalisation and mortality after acute heart failure hospitalisation: a competing risk analysis Marques, Irene Mendonça, Denisa Teixeira, Laetitia Open Heart Heart Failure and Cardiomyopathies OBJECTIVE: To identify factors that independently predict the risk of rehospitalisation and death after acute heart failure (AHF) hospital discharge in a real-world setting, considering death without rehospitalisation as a competing event. METHODS: Single-centre, retrospective, observational study enrolling 394 patients discharged from an index AHF hospitalisation. Overall survival was evaluated using Kaplan-Meier and Cox regression models. For the risk of rehospitalisation, survival analysis considering competing risks was performed: rehospitalisation was the event of interest, and death without rehospitalisation was the competing event. RESULTS: During the first year after discharge, 131 (33.3%) patients were rehospitalised for AHF and 67 (17.0%) died without being readmitted; the remaining 196 patients (49.7%) lived without further hospitalisations. The 1-year overall survival estimate was 0.71 (SE=0.02). After adjusting for gender, age and left ventricle ejection fraction, the results showed that the risk of death was higher in patients with dementia, higher levels of plasma creatinine (PCr), lower levels of platelet distribution width (PDW) and at Q4 of red cell distribution width (RDW). Multivariable models showed that the risk of rehospitalisation was increased in patients with atrial fibrillation, higher PCr or taking beta-blockers at discharge. Furthermore, the risk of death without AHF rehospitalisation was higher in males, those aged ≥80 years, patients with dementia or RDW at Q4 on admission (compared with Q1). Taking beta-blockers at discharge and having a higher PDW on admission reduced the risk of death without rehospitalisation. CONCLUSION: When assessing rehospitalisation as a study endpoint, death without rehospitalisation should be considered a competing event in the analyses. Data from this study reveal that patients with atrial fibrillation, renal dysfunction or taking beta-blockers are more likely to be rehospitalised for AHF, while older men with dementia or high RDW are more prone to die without hospital readmission. BMJ Publishing Group 2023-03-20 /pmc/articles/PMC10030761/ /pubmed/36941025 http://dx.doi.org/10.1136/openhrt-2022-002167 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Heart Failure and Cardiomyopathies
Marques, Irene
Mendonça, Denisa
Teixeira, Laetitia
One-year rehospitalisation and mortality after acute heart failure hospitalisation: a competing risk analysis
title One-year rehospitalisation and mortality after acute heart failure hospitalisation: a competing risk analysis
title_full One-year rehospitalisation and mortality after acute heart failure hospitalisation: a competing risk analysis
title_fullStr One-year rehospitalisation and mortality after acute heart failure hospitalisation: a competing risk analysis
title_full_unstemmed One-year rehospitalisation and mortality after acute heart failure hospitalisation: a competing risk analysis
title_short One-year rehospitalisation and mortality after acute heart failure hospitalisation: a competing risk analysis
title_sort one-year rehospitalisation and mortality after acute heart failure hospitalisation: a competing risk analysis
topic Heart Failure and Cardiomyopathies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030761/
https://www.ncbi.nlm.nih.gov/pubmed/36941025
http://dx.doi.org/10.1136/openhrt-2022-002167
work_keys_str_mv AT marquesirene oneyearrehospitalisationandmortalityafteracuteheartfailurehospitalisationacompetingriskanalysis
AT mendoncadenisa oneyearrehospitalisationandmortalityafteracuteheartfailurehospitalisationacompetingriskanalysis
AT teixeiralaetitia oneyearrehospitalisationandmortalityafteracuteheartfailurehospitalisationacompetingriskanalysis